Tumor Microenvironment Characteristics and Prognostic Role of MA Modification in Lung Squamous Cell Carcinoma

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Mar 8

PMID 38455573

Authors

Pei Li

Peiyu Xiong

Xinyun Li

Xiaobo Zhang

Xu Chen

Wei Zhang

Bo Jia

Yu Lai

Affiliations

Soon will be listed here.

Abstract

Background: It has recently been determined that N6-methyladenosine (mA) RNA methylation regulators have prominent effects on several cancers. However, the potential role of mA modification in lung squamous cell carcinoma (LUSC) remains unclear.

Methods: We evaluated the modification pattern of mA and studied the biological function of mA regulators in LUSC. Then, we constructed the m6Ascore to predict the prognosis of LUSC and analyzed the relationship between the m6Ascore and tumor mutation burden, immune cell infiltration, and immunotherapy.

Result: In the unsupervised consensus cluster analysis, three different m6Aclusters were identified, which correspond to an immune activation state, a moderate immune activation state, and an immune tolerance state. Forty-two genes related to the mA phenotype were used to construct the m6Ascore; subsequently, multiple validations of the m6Ascore were carried out to determine the relationship between the score and immune cell infiltration and response to CTLA-4/PD-1 inhibitor treatment. Further analysis revealed that the m6Ascore could effectively predict the prognosis of LUSC and that the mA phenotype-related genes, and , might be potential biomarkers.

Conclusion: These findings highlight the potential role of mA modification in the prognosis, TME, and immunotherapy of LUSC and have profound implications for developing more effective personalized treatment strategies for LUSC.

Citing Articles

A novel hypoxia- and lactate metabolism-related prognostic signature to characterize the immune landscape and predict immunotherapy response in osteosarcoma.

Wang Y, Wang X, Liu Y, Xu J, Zhu J, Zheng Y Front Immunol. 2024; 15:1467052.

PMID: 39569192 PMC: 11576178. DOI: 10.3389/fimmu.2024.1467052.

RNA modifications in cancer immune therapy: regulators of immune cells and immune checkpoints.

Qin X, Liu H, Zhang Q, Che Y, Lei T, Tang F Front Immunol. 2024; 15:1463847.

PMID: 39372415 PMC: 11449722. DOI: 10.3389/fimmu.2024.1463847.

References

Liu J, Eckert M, Harada B, Liu S, Lu Z, Yu K . mA mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018; 20(9):1074-1083. PMC: 6245953. DOI: 10.1038/s41556-018-0174-4. View

Morse M, Overman M, Hartman L, Khoukaz T, Brutcher E, Lenz H . Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. Oncologist. 2019; 24(11):1453-1461. PMC: 6853093. DOI: 10.1634/theoncologist.2019-0129. View

Chumsri S, Sokol E, Soyano-Muller A, Parrondo R, Reynolds G, Nassar A . Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature. J Natl Compr Canc Netw. 2020; 18(5):517-521. DOI: 10.6004/jnccn.2020.7543. View

Zhang W, Zhang Q, Xie Z, Che L, Xia T, Cai X . -Methyladenosine-Related Long Non-Coding RNAs Are Identified as a Potential Prognostic Biomarker for Lung Squamous Cell Carcinoma and Validated by Real-Time PCR. Front Genet. 2022; 13:839957. PMC: 9204524. DOI: 10.3389/fgene.2022.839957. View

Overman M, McDermott R, Leach J, Lonardi S, Lenz H, Morse M . Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017; 18(9):1182-1191. PMC: 6207072. DOI: 10.1016/S1470-2045(17)30422-9. View

Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y . R-2HG Exhibits Anti-tumor Activity by Targeting FTO/mA/MYC/CEBPA Signaling. Cell. 2017; 172(1-2):90-105.e23. PMC: 5766423. DOI: 10.1016/j.cell.2017.11.031. View

Bai Y, Yang C, Wu R, Huang L, Song S, Li W . YTHDF1 Regulates Tumorigenicity and Cancer Stem Cell-Like Activity in Human Colorectal Carcinoma. Front Oncol. 2019; 9:332. PMC: 6509179. DOI: 10.3389/fonc.2019.00332. View

Li Z, Weng H, Su R, Weng X, Zuo Z, Li C . FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N-Methyladenosine RNA Demethylase. Cancer Cell. 2016; 31(1):127-141. PMC: 5234852. DOI: 10.1016/j.ccell.2016.11.017. View

Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J . Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006; 98(4):262-72. DOI: 10.1093/jnci/djj052. View

10.

Li L, Liu Y, Zhan Y, Zhu Y, Li Y, Xie D . High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma. Thorac Cancer. 2018; 9(7):775-784. PMC: 6026602. DOI: 10.1111/1759-7714.12643. View

11.

Yang Z, Li J, Feng G, Gao S, Wang Y, Zhang S . MicroRNA-145 Modulates -Methyladenosine Levels by Targeting the 3'-Untranslated mRNA Region of the -Methyladenosine Binding YTH Domain Family 2 Protein. J Biol Chem. 2017; 292(9):3614-3623. PMC: 5339747. DOI: 10.1074/jbc.M116.749689. View

12.

Kim G, Siddiqui A . N6-methyladenosine modification of HCV RNA genome regulates cap-independent IRES-mediated translation via YTHDC2 recognition. Proc Natl Acad Sci U S A. 2021; 118(10). PMC: 7958429. DOI: 10.1073/pnas.2022024118. View

13.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

14.

Qian L, Lin L, Du Y, Hao X, Zhao Y, Liu X . MicroRNA-588 suppresses tumor cell migration and invasion by targeting GRN in lung squamous cell carcinoma. Mol Med Rep. 2016; 14(4):3021-8. PMC: 5042737. DOI: 10.3892/mmr.2016.5643. View

15.

Cai J, Zhou M, Xu J . N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma. World J Surg Oncol. 2021; 19(1):241. PMC: 8364031. DOI: 10.1186/s12957-021-02354-8. View

16.

Liu J, Zhang X, Chen K, Cheng Y, Liu S, Xia M . CCR7 Chemokine Receptor-Inducible lnc-Dpf3 Restrains Dendritic Cell Migration by Inhibiting HIF-1α-Mediated Glycolysis. Immunity. 2019; 50(3):600-615.e15. DOI: 10.1016/j.immuni.2019.01.021. View

17.

Negishi M, Wongpalee S, Sarkar S, Park J, Lee K, Shibata Y . A new lncRNA, APTR, associates with and represses the CDKN1A/p21 promoter by recruiting polycomb proteins. PLoS One. 2014; 9(4):e95216. PMC: 3991591. DOI: 10.1371/journal.pone.0095216. View

18.

Liu S, Li Q, Chen K, Zhang Q, Li G, Zhuo L . The emerging molecular mechanism of mA modulators in tumorigenesis and cancer progression. Biomed Pharmacother. 2020; 127:110098. DOI: 10.1016/j.biopha.2020.110098. View

19.

El-Khoueiry A, Sangro B, Yau T, Crocenzi T, Kudo M, Hsu C . Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389(10088):2492-2502. PMC: 7539326. DOI: 10.1016/S0140-6736(17)31046-2. View

20.

Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View